Sun Pharma Signs Global Licensing Deal with LIB Therapeutics for Lerodalcibep

Key numbers

Market Cap	₹444,404.83 CrLarge Cap
Revenue TTM	₹59,910.52 CrOperating Revenue
Net Profit TTM	₹12,095.58 CrProfitability
P/E TTM	36.74Industry PE 48.32
Order from	LIB Therapeutics Inc.

Key highlights

• Sun Pharma gains exclusive rights to manufacture and commercialize Lerodalcibep worldwide, excluding US and China
• Lerodalcibep received European Union approval on September 21, 2026, under the brand name Lyrokaul
• The target PCSK9 inhibitor market ex-US and China reached $3.7 billion in MAT Q2 2026, growing at a 38% CAGR
• Financial terms include upfront and future milestone payments plus royalties based on net sales
• The therapy is a once-monthly injection designed for LDL-cholesterol reduction in high-risk patients

What Is the Partnership?

Sun Pharmaceutical Industries has secured an exclusive licensing agreement with LIB Therapeutics Inc. to bring lerodalcibep to global markets, specifically excluding the United States and China. Under the terms of the deal, Sun Pharma will handle the manufacturing and commercialization responsibilities within these licensed territories.

In exchange, LIB Therapeutics will receive an upfront payment along with future milestone-linked payments. Additionally, Sun Pharma will pay royalties based on net sales of the product in the specified regions. This collaboration leverages Sun Pharma's established international manufacturing footprint and commercial infrastructure to scale the reach of this cardiovascular biologic.

Partner Profile

LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company headquartered in Cincinnati, Ohio. The firm focuses on developing novel, highly effective therapies for patients with cardiovascular disease and familial hypercholesterolemia. Its lead candidate, lerodalcibep, is a third-generation PCSK9 inhibitor designed to overcome the limitations of early-generation monoclonal antibodies.

By utilizing an antibody-mimetic biologic and recombinant fusion protein approach, LIB has developed a small-volume, once-monthly injection that maintains potency while offering enhanced storage stability at room temperature, making it a competitive entrant in the global lipid-lowering market.

What It Unlocks

• Immediate access to a US$3.7 billion PCSK9 inhibitor market outside the US and China
• European commercialization following EU approval as of September 21, 2026
• Entry into a therapeutic segment growing at a 38% compound annual growth rate
• Strengthening of the 'Innovative Medicines' portfolio which contributes 22% of company sales
• Competitive advantages through six-month ambient storage and once-monthly dosing

Strategic Alignment

This agreement marks a significant step in strengthening our global Innovative Medicines portfolio, particularly in cardiovascular care. With exclusive rights outside the United States and China, we look forward to expanding access to this important treatment option for patients globally.

Industry Landscape

The global pharmaceutical industry is witnessing a shift toward biologic therapies for chronic conditions like hypercholesterolemia, where traditional statins often fall short of clinical goals. Only 33% of high-risk patients on stable oral therapies currently achieve their LDL-cholesterol targets, creating a significant clinical gap. PCSK9 inhibitors represent the standard of care for these difficult-to-treat cases.

As patent cliffs approach for older molecules, large pharmaceutical players are increasingly pivoting toward specialty and innovative biologics through strategic licensing. This trend is driven by high growth rates in the non-US market, which is expected to approach US$7 billion globally by the end of 2026.

“Sun Pharma’s international presence and experience in building global innovative brands make it an ideal partner to bring lerodalcibep to more patients. Together, we aim to expand access for patients with cardiovascular disease, or at high cardiovascular risk, who need substantial additional LDL-cholesterol reductions despite existing treatment.”

Sun Pharmaceutical Industries · financial snapshot

Share price	₹1852.2
Market capitalisation	₹4.44L Cr
Revenue (annual)	₹58,462.04 Cr
Net profit (annual)	₹11,479.42 Cr
P/E (TTM)	36.74×Sector 50.35×
Promoter holding	54.48%0.00% QoQ
FII holding	14.54%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.